Prostate cancer — all decisions

The Board denied service connection for dermatochalasis, meibomian gland dysfunction, and blepharitis. The claims for lumbosacral strain, left lower extremity radiculopathy (sciatic nerve), right shoulder tendinopathy, diabetes, and prostate cancer with urinary incontinence status-post prostatectomy were remanded.

The Board granted a disability rating of 60 percent for the residuals of prostate cancer and seminoma right testis with retroperitoneal metastasis, finding that the evidence supports the need to change absorbent material more than four times per day.

The Board denied service connection for multiple conditions, including rheumatoid arthritis, right hip degenerative joint disease and rheumatoid arthritis with acetabular cyst status post right total hip replacement, osteoarthritis, psoriatic arthritis, hypertension, prostate cancer, diabetes mellitus type II, fever sores, and a compromised immune system, as the evidence did not support a finding of service connection for any of these conditions.

The Board denied the veteran's claim for service connection for a prostate condition, including prostate cancer, as there was no evidence of an in-service injury or disease and no nexus to service.

The appeal for service connection for prostate cancer was dismissed due to an impermissible concurrent election of decision review options.

The Board denied the Veteran's claims for a higher disability rating for bladder cancer and prostate cancer, finding that the evidence did not support ratings in excess of 40 percent.

The Board denied service connection for arthritis of all joints from head to toe, sleep apnea, prostate cancer, high blood pressure, a right knee disability, and a left knee disability as there was no evidence of current diagnoses or etiological relationships to the Veteran's service.

The Board granted an effective date of March 15, 2023, for a 40 percent evaluation for service-connected prostate cancer and earlier dates for the awards of service connection for anterior and posterior trunk scars.

The Board denied the Veteran's claim for an earlier effective date prior to December 30, 2023, for the assignment of a 100 percent evaluation for service-connected prostate cancer.

The Board denied service connection for prostate cancer and erectile dysfunction, finding no evidence of a causal relationship between the conditions and the Veteran's active duty service.

The Board granted readjudication of the claims for service connection for diabetes mellitus, prostate cancer, and peripheral neuropathy of the left and right lower extremities due to new and relevant evidence having been received.

The Board remands the claims for earlier effective dates and increased ratings to cure a pre-decisional duty to assist error related to the Veteran's exposure to herbicide agents in Thailand.

The Board denied the veteran's claim for service connection for a prostate disability, claimed as prostate cancer, due to a lack of evidence supporting a current diagnosis and a link to service.

The Board granted the restoration of a 60 percent evaluation for prostate cancer with incontinence, voiding dysfunction, and urinary frequency effective March 1, 2025.

The Board denied increased ratings for hypertension and prostate cancer with bladder cancer, status post TURBT and radiation therapy, as well as entitlement to a total disability rating due to individual unemployability (TDIU) for the periods from May 19, 2020 to June 25, 2020, and from August 1, 2022.

The Board denied initial ratings in excess of 50 percent for unspecified trauma and stressor-related disorder, and unspecified depressive disorder; in excess of 10 percent for residuals of prostate cancer; and a compensable rating for erectile dysfunction.

The Board denied service connection for residuals of colon cancer and prostate cancer, finding no evidence linking the conditions to the Veteran's in-service asbestos exposure.

The Board denied the veteran's claim for service connection for prostate cancer, finding no medical evidence linking the condition to his active-duty service or toxic exposure risk activity.

The Board granted service connection for prostate cancer based on new and relevant evidence that established a link between the Veteran's in-service exposure to PFAS and his development of prostate cancer.

The Board denied the Veteran's claim for an earlier effective date for a 100 percent disability rating for prostate cancer with residuals of radiation cystitis status post bladder removal with urostomy, finding that the evidence did not support an earlier entitlement date.